Bullish & Foolish
Full COCP fundamentals All 466 on the Survival Watch

COCPCOCRYSTAL PHARMA, INC.

Is Cocrystal Pharma struggling financially?

Yes, by its own account. Cocrystal Pharma told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Grant funding

    The risk-free interest rate is estimated using comparable published federal funds rates. Grant Income The Company accounts for government grant funding by analogy to ASC 958-605 because U.S. GAAP does not contain specific guidance for business entities receiving government grants.

    Form 10-Q, filed 15 May 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$22.2M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$8.2M

What Cocrystal Pharma told the SEC

…2026, the Company recorded a net loss of approximately $ 2,299,000 and used approximately $ 2,340,000 of cash in operating activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025 financial statements, has expressed substantial doubt about…

COCRYSTAL PHARMA, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 35.5% share-count increase The company issued stock. Each share now owns 26.2% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 67% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt